drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy
drug_description
Allogeneic, genetically modified natural killer cells engineered to express an anti-BCMA chimeric antigen receptor that recognizes BCMA (TNFRSF17) on malignant plasma cells and triggers NK-mediated cytotoxicity and cytokine release to kill tumor cells.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Receptors, Chimeric Antigen
drug_category
CAR NK
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Allogeneic NK cells engineered to express an anti-BCMA chimeric antigen receptor bind BCMA (TNFRSF17) on malignant plasma cells, activating NK and CAR signaling to induce perforin/granzyme-mediated cytotoxicity and cytokine release, resulting in tumor cell apoptosis.
drug_name
Human BCMA-targeted CAR-NK cells
nct_id_drug_ref
NCT06045091